Evidence map›Paper›PMID 42443573›Full record

ArticleDoklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections2026

N-Isocaproyl-L-Arginylglycine Hexamethylenediamide, First Low-Molecular-Weight Mimetic of Neurotrophin-4: Design and Neuroprotective Activity.

T A Gudasheva, N I Sokolenko, K N Kolyasnikova, T A Antipova, L F Zainullina, M S Sergeeva, V L Dorofeev

Abstract read
PubMed Publisher
In one paragraph

Article in Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

T A GudashevaFederal Research Center of Original and Promising Biomedical and Pharmaceutical Technologies, Moscow, Russia. gudasheva_ta@academpharm.ru.
N I SokolenkoFederal Research Center of Original and Promising Biomedical and Pharmaceutical Technologies, Moscow, Russia.
K N KolyasnikovaFederal Research Center of Original and Promising Biomedical and Pharmaceutical Technologies, Moscow, Russia.
T A AntipovaFederal Research Center of Original and Promising Biomedical and Pharmaceutical Technologies, Moscow, Russia.
L F ZainullinaFederal Research Center of Original and Promising Biomedical and Pharmaceutical Technologies, Moscow, Russia.
M S SergeevaFederal Research Center of Original and Promising Biomedical and Pharmaceutical Technologies, Moscow, Russia.
V L DorofeevFederal Research Center of Original and Promising Biomedical and Pharmaceutical Technologies, Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A dimeric dipeptide mimetic of neurotrophin-4 (NT-4), N-isocaproyl-L-arginylglycine hexamethylenediamide (GZS-411), was designed based on the β-turn structure of NT-4 loop 1. GZS-411 activated the TrkB receptor similarly to the full-size neurotrophin. Neuroprotective activity of GZS-411 was observed in vitro with HT-22 mouse hippocampal cells exposed to oxidative stress or glutamate toxicity and was exerted at concentrations from 10

Indexed as

DipeptidesNerve Growth FactorsNeuroprotective AgentsAnimalsCell Line, TumorHippocampusHumansMiceOxidative StressOxidopamineReceptor, trkBDipeptidesNerve Growth FactorsNeuroprotective Agentsneurotrophin 4OxidopamineReceptor, trkBdipeptide GZS-411mimeticneuroprotective activityneurotrophin-4Trk receptors

Identifiers

PMID42443573

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.